Patient Journey Guides

Alzheimer's Follow-up After Care in China: Making the Return-Home Plan Work

A consultation or treatment course in China becomes useful over time only if its findings can be incorporated into care where the patient lives. Prescriptions, monitoring, support with daily activities, and urgent assessment usually depend on the local health system after the journey ends. Bringing home a discharge summary is necessary, but continuity requires agreement about who will act on its recommendations.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

  • The handover should state the clinical diagnosis, current functional stage, supporting investigations, and remaining uncertainties. It should identify current medicines, actual doses and routes, reasons for recent changes, important adverse reactions, and the date of the most recent treatment. Any result still pending needs an identified person responsible for communicating it.
  • As blood biomarkers become more available, families may hope that repeated blood tests can replace MRI, PET, or clinical review. A test cleared to aid diagnosis is not necessarily validated for monitoring individual treatment response. Roche's 2026 announcement for its FDA-cleared p-tau217 assay specifically states limitations concerning prediction of future progression and monitoring response to treatment.
  • Sleep deprivation, illness, work disruption, and inability to sustain supervision are relevant clinical information. Ask local providers about available home support, day services, respite, or social work assistance, then check what can actually be accessed. A plan that relies indefinitely on one exhausted person may need adjustment even when the patient's prescription has not changed.

Quick answer

A consultation or treatment course in China becomes useful over time only if its findings can be incorporated into care where the patient lives. Prescriptions, monitoring, support with daily activities, and urgent assessment usually depend on the local health system after the journey ends. Bringing home a discharge summary is necessary, but continuity requires agreement about who will act on its recommendations.

Full guide

A consultation or treatment course in China becomes useful over time only if its findings can be incorporated into care where the patient lives. Prescriptions, monitoring, support with daily activities, and urgent assessment usually depend on the local health system after the journey ends. Bringing home a discharge summary is necessary, but continuity requires agreement about who will act on its recommendations.

Before leaving China, identify the local clinician or service expected to continue each part of the plan. If no one can provide a required infusion, MRI examination, or timely review, tell the original treating team. That gap may require a change in the proposed treatment arrangement. International travel is not a dependable emergency pathway, and a prescription issued abroad should not be assumed to be dispensable in the country of residence.

Arrange an explicit handover

The handover should state the clinical diagnosis, current functional stage, supporting investigations, and remaining uncertainties. It should identify current medicines, actual doses and routes, reasons for recent changes, important adverse reactions, and the date of the most recent treatment. Any result still pending needs an identified person responsible for communicating it.

Ask the Chinese team to distinguish work that can be managed locally from questions requiring further specialist discussion. The receiving clinician should confirm which responsibilities they can accept. Sending a report does not establish that another service has agreed to prescribe an antibody or that it can arrange the imaging and review required before a future dose.

A concise bilingual summary can help both teams check dates and medicine names, with the full original records available behind it. Update the summary whenever either team changes the plan. Otherwise, two well-intentioned clinicians may make separate adjustments without knowing which version the household is following. The family should also know whom to contact if recommendations appear inconsistent.

Give different follow-up tasks their own timetable

A broad dementia review considers cognition, everyday abilities, behavior, nutrition, mobility, and the demands on caregivers. A check after starting or changing a medicine may need to happen sooner. Anti-amyloid care adds scheduled MRI examinations and decisions about whether treatment can proceed. These tasks cannot all be represented adequately by a single instruction to return in six months.

The responsible clinician should set intervals according to the medicine, recent changes, symptoms, and individual risks. In the household calendar, include when results should be available and who will review them, not only the date of the scan or clinic visit. Confirm the route for advice outside ordinary clinic hours, particularly when international time differences and public holidays affect communication.

If a required investigation cannot be completed on time, contact the treating service before assuming the delay is harmless. Missed tablets, postponed injections, and restarting after an interruption have medicine-specific implications. The appropriate action should come from the current prescription instructions and clinical team rather than an improvised catch-up schedule.

Continue the MRI process throughout antibody care

Lecanemab and donanemab can cause amyloid-related imaging abnormalities, including edema and hemorrhagic changes. Some findings occur without obvious symptoms. Looking well at home therefore cannot replace surveillance that the treatment requires. Before continuing locally, establish whether the imaging service can perform an appropriate examination, provide the images, and return an interpretation in time for a treatment decision.

As of September 2026, the July US lecanemab label describes MRI monitoring at approximately months one, two, three, and six after treatment begins. The US donanemab label specifies baseline MRI and scans before the second, third, fourth, and seventh infusions. These examples show why the correct product and current version matter. Continuing care must follow the applicable approved information in the country of treatment and the responsible clinician's assessment.

There must also be a decision after the report becomes available. A new finding may require interruption, more investigation, or additional monitoring. Families should not interpret wording such as “mild” as permission to proceed without review. Changing a formulation or entering a maintenance regimen does not eliminate safety follow-up. A report, a reviewed report, and a decision to give the next dose are separate steps.

Make important treatment information accessible in an emergency

Prepare a short treatment note with the diagnosis, antibody name, last administration date, important accompanying medicines, allergies, and clinical contacts. Follow the team's advice about reporting new headache, visual change, dizziness, altered awareness, gait difficulty, or other concerning symptoms. Sudden weakness, speech disturbance, a seizure, or a severe change in consciousness needs the local emergency response.

Symptoms of ARIA can overlap with those of other acute neurological conditions. Emergency clinicians need the treatment history to interpret that situation and choose appropriate investigations. The household should not attempt to distinguish stroke from ARIA independently or decide which acute medicine should be given. Waiting at home for a reply from an overseas clinic can delay necessary assessment.

Keep the treatment note somewhere a companion can access it even if the patient's phone is unavailable. If several relatives share care, make sure they all understand that the note supports local emergency treatment; it is not a substitute for seeking it. Update the information after an interruption, restart, or change in the antibody regimen.

Observe changes that can be described reliably

A small number of meaningful observations usually helps more than a demanding daily scoring exercise. Depending on the person's needs, the family might record the assistance required for a familiar activity, night waking, food intake, weight change, falls, or difficulty taking medicines. Note when a change began, whether it persists, and whether illness or a prescription change occurred at the same time.

Repeatedly asking the person identical memory questions may increase pressure without providing a valid measure of treatment response. Formal cognitive assessment needs an appropriate interval and interpretation of language, testing conditions, fatigue, and practice effects. Clinicians should compare test results with everyday function and observations from someone who knows the person well.

Anti-amyloid trials demonstrate an average slowing of decline in their study populations. A better conversation on one afternoon cannot be converted into a personal percentage of benefit, and continued decline does not by itself show what would have happened without treatment. Follow-up should assess the overall clinical picture, treatment burden, and the person's goals rather than promise an individual counterfactual that cannot be measured directly.

Do not turn a blood result into an automatic stopping rule

As blood biomarkers become more available, families may hope that repeated blood tests can replace MRI, PET, or clinical review. A test cleared to aid diagnosis is not necessarily validated for monitoring individual treatment response. Roche's 2026 announcement for its FDA-cleared p-tau217 assay specifically states limitations concerning prediction of future progression and monitoring response to treatment.

If a clinician requests repeat biomarker testing, ask what question the result is intended to answer and how it could change management. A lower value does not demonstrate restored memory or the disappearance of hemorrhagic risk. Likewise, a change between laboratories may not have the same interpretation as a change measured consistently with a validated method.

Donanemab prescribing information allows consideration of stopping treatment after amyloid has been reduced to minimal levels on PET. This is a product-specific clinical decision. It should not be rewritten as a fixed course that permanently cures Alzheimer's disease. The discussion should include the relevant evidence, local requirements, uncertainty about subsequent management, and the patient's circumstances.

Reassess symptomatic medicines as well

Donepezil, rivastigmine, galantamine, and memantine require attention to tolerability, functional change, treatment goals, and actual adherence. Nausea, poor appetite, weight loss, fainting, or another suspected adverse effect should be communicated to the clinician. Ending a trip does not itself justify stopping these medicines, and disease severity alone should not trigger an automatic withdrawal of an acetylcholinesterase inhibitor.

Where burdens appear to outweigh likely benefit, a clinician may discuss a monitored reduction of a cognitive enhancer. The plan should explain the intended outcome, observation period, and changes that would prompt reconsideration. Evidence on withdrawal has limitations and does not provide one stopping date suitable for everyone. Changing several medicines simultaneously can also make it difficult to understand why a person improves or deteriorates.

Medicines used for agitation or other behavioral symptoms need their own review. NICE advises reassessing ongoing antipsychotic treatment at least every six weeks, with earlier contact for adverse effects or a change in the situation. Approval of a new treatment in the United States does not automatically make it an available option in China or the country of residence. A local prescriber should check any proposed substitution, formulation change, or switch to another drug class.

Treat abrupt worsening as a new clinical question

Marked confusion, sleepiness, or reduced activity developing over hours or days may reflect delirium or another acute condition. Infection, dehydration, pain, constipation, and medicine effects are possible contributors. Compare the person with their usual state and obtain timely medical assessment. Recent intake, bowel pattern, sleep, and prescription changes can help the clinician investigate.

A positive urine finding does not necessarily explain every cognitive change. The IDSA guideline advises looking for other causes and observing, rather than automatically prescribing antibiotics, when an older person with cognitive or functional impairment has bacteriuria and delirium without local urinary symptoms or systemic signs such as fever or hemodynamic instability. Signs of serious infection require urgent clinical management; the recommendation must not be used to dismiss them.

After an acute episode, the follow-up plan may need revision. The person may have different care needs, and medicines or mobility may have changed during hospitalization. The original dementia schedule should be reconsidered in that new context rather than resumed without checking what happened.

Adapt the home to the current level of support

In a hospital, staff may have supervised walking, medicine administration, and meals. Those supports can disappear when a person returns home. Review how medicines are stored and given, whether kitchen appliances remain safe to use, and whether loose rugs, cords, poor nighttime lighting, or slippery bathroom surfaces create avoidable hazards. Adaptations should support retained abilities while addressing actual risks.

New choking, swallowing difficulty, weight loss, or substantially slower eating should lead to appropriate assessment. Adding supplements without investigating the cause can miss a problem that needs a different response. Concerns about wandering or driving also need discussion with local clinicians and services, including the rules that apply where the person lives.

A change of residence or caregiver should be reported because it may alter what the care plan can realistically achieve. Recommendations from a Chinese specialist need to fit the services and practical resources available at home. The same brand name, appointment frequency, or type of home support may not be available in both places.

Include the caregiver's capacity in the review

Sleep deprivation, illness, work disruption, and inability to sustain supervision are relevant clinical information. Ask local providers about available home support, day services, respite, or social work assistance, then check what can actually be accessed. A plan that relies indefinitely on one exhausted person may need adjustment even when the patient's prescription has not changed.

Continue conversations about the patient's preferences and future care while supporting their participation as far as possible. Preferences about familiar people, meaningful activities, comfort, and treatment burden can guide later decisions. At the end of a follow-up visit, the household should understand the current goal, the next action, and the contact for a problem. That practical clarity is what turns an overseas consultation into continuing care.

Sources

Related guides